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Abstract 1 
 2 
Particle inhalation is an effective and rapid delivery method for a variety of pharmaceuticals, 3 
particularly bronchodilation drugs used for treating asthma and COPD. Conditions of relative humidity 4 
and temperature inside the lungs are generally very different from the outside ambient air, with the 5 
lung typically being warmer and more humid. Changes in humidity, from inhaler to lung, can cause 6 
hygroscopic phase transitions and particle growth.  Changing Increasing particle size and mass can 7 
negatively affect particle deposition within the lung leading to inefficient treatment, while 8 
deliquescence prior to impaction is liable to accelerate drug uptake.  To better understand the 9 
hygroscopic properties of four pharmaceutical aerosol particles; pharmaceutical particles from four 10 
commercially available pressurised metered dose inhalers (pMDIs) were stably captured in an optical 11 
trap, and their composition was examined online via Raman spectroscopy.  Micron-sized particles of 12 
salbutamol sulfate, salmeterol xinafoate, fluticasone propionate and ciclesonide were levitated and 13 
examined over a range of relative humidity values inside a chamber designed to mimic conditions 14 
within the respiratory tract. The effect of temperature upon hygroscopicity was also investigated for 15 
salbutamol sulfate particles. Salbutamol sulfate was found to have significant hygroscopicity, 16 
salmeterol xinafoate showed some hygroscopic interactions, whilst fluticasone propionate and 17 
ciclesonide revealed no observable hygroscopicity.  Thermodynamic and structural modelling is used 18 
to explain the observed experimental results. 19 
 20 
1. Introduction 21 
1.1 Respiratory drugs and drug delivery 22 
Respiratory ailments in the form of asthma and Chronic Obstructive Pulmonary Disease (COPD) are 23 
often managed with inhalable drugs. These drugs include beta-2 agonists such as salbutamol and 24 
salmeterol, and corticosteroids like fluticasone and ciclesonide. 25 
Salbutamol sulfate and salmeterol xinafoate are both beta-2 andrenoceptor agonists, meaning that 26 
they target the beta-2 receptors in bronchial muscle cells in a similar manner to adrenaline (Reisine, 27 
et al., 1983), forcing calcium out of the cells thus forcing them to relax, and opening the user’s airways 28 
to allow easier breathing. Salbutamol (Ventalin™, Salamol™) has been a popular treatment for asthma 29 
and COPD since 1968 (Icha, 2007), while Salmeterol (Serevent™) was introduced in 1988 as a longer 30 
lasting alternative (Ullman & Svedmyr, 1988). 31 
Fluticasone propionate (Flixotide™) is an artificial corticosteroid that assists breathing by reducing 32 
inflammation in the lung lining (Harding, 1990). Fluticasone propionate is also supplied as a 33 
combination inhaler with salmeterol xinafoate (Seretide™) due to their complementary modes of 34 
action (Woolcock, et al., 1996) (Chapman, et al., 1999) (Calverley, et al., 2003). Pure compounds rather 35 
than mixtures were investigated in this study. 36 
Ciclesonide (Alvesco™) is a recently developed inhaled corticosteroid used as a treatment for asthma, 37 
hay fever and other respiratory ailments. In order to reduce the mouth and throat infections 38 
associated with respiratory steroid application, ciclesonide is designed to be biologically inactive until 39 
it interacts with esterase enzymes present in the lung (Mutch, et al., 2007) at which point it is 40 
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hydrolysed to the active form desisobutyryl-ciclesonide; these enzymes are not found in the oral cavity 1 
to the same extent, and hence the potential benefit of reduced oropharyngeal side effects.  2 
Inhalable drugs are predominately administered by nebuliser, dry powder inhaler (DPI) or by 3 
pressurised metered dose inhaler (pMDI). Powdered nebulisers have been in use since the 19th century 4 
(Sanders, 2007), while cheaper and more portable pMDIs were invented in 1955 (Purewal & Grant, 5 
1997). The pMDI is now the most popular device for delivering drugs to the human respiratory system 6 
in Great Britain and elsewhere (Lavorini, et al., 2011). 7 
Modern pMDIs contain solid drug particles which are suspended in a liquefied hydrofluoroalkane 8 
propellant: most commonly HFA-134a (Cripps, et al., 2000) (Leach, 2005). Other co-solvents such as 9 
ethanol or oleic acid can be used depending on the drug (Bell & Newman, 2007). The solvent 10 
rapidlyevaporates within a few milliseconds at ambient temperature upon activation of the pMDI 11 
(Stein, 2006), generating a fixed dose, inhalable aerosol of micron-sized solid drug particles travelling 12 
at a wide range of planar velocities into the user’s trachaea and lungs (Crosland, et al., 2009). 13 
1.2 Significance of relative humidity and temperature on delivery efficiency 14 
Drugs acting within the respiratory tract are only effective if the particle aerodynamic diameters are 15 
in the 1-5µm range since larger particles cannot reach the receptor sites inside the lungs (Labiris & 16 
Dolovich, 2003). Hygroscopic particles can change increase in size and mass as they collect water from 17 
the air (Broday & Georgopoulos, 2001) which means that particles manufactured in the correct 18 
sizeappropriate range when dry may swell to larger than optimal size and higher than optimal mass 19 
by the time they pass through the moist air inside the trachea and into towards the lungs. While larger 20 
particles are less likely to navigate to the regions where they can be absorbed most rapidly, more 21 
massive particles have greater momentum, are more likely to impact the back of the throat than pass 22 
into the lungs (Mansour, et al., 2016) and their direction of travel is less influenced by the Brownian 23 
diffusion processes that would drive them to their intended destination (Tsuda, et al., 2013). 24 
Previous work has shown (Tong, et al., 2014) that salbutamol sulfate deliquesces at around 92% 25 
relative humidity (RH). Deliquescence describes the phase change of a crystalline solid to a saturated 26 
solution droplet using water collected from the surrounding air. Temperature can affect the RH level 27 
required to bring about deliquescence in hygroscopic substances but the effect varies between 28 
compounds (Lipasek, et al., 2013). Temperature also has a significant influence over the saturation 29 
vapour pressure of air (Lawrence, 2005) so the air inside the lungs at 37oC and near-100% RH contains 30 
three times the concentration of water as outside air at similar RH and 20oC (Nave, 2004). However, 31 
temperature influences the kinetics of drug dissolution only, rather than the thermodynamic 32 
behaviour of solid particles, which remain relatively unchanged, and it is not expected to significantly 33 
impact hygroscopic properties. 34 
The rate of deliquescence dictates the rate of adsorption of drugs across lung epithelia, since a given 35 
drug cannot be absorbed until it has fully dissolved (Bikiaris, 2011). This lends a time-critical aspect to 36 
drug delivery since solid particles in the lungs are removed over time by ejection via the mucociliary 37 
escalator in the ciliated regions of the lungs or partition into macrophages in the alveoli (Hardy & 38 
Chadwick, 2000) and dissolution appears to be the rate-limiting step for the uptake of inhalable drugs 39 
(Bur, et al., 2010). If more of a given drug is removed in these manners before itis fully dissolved, a 40 
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greater dose must be administered and the resultant side effects such as immunosuppression with 1 
corticosteroids (Lee, et al., 2012) and hypoalkaemia with salbutamol (Hung, et al., 1999) will have 2 
greater impacts on patient health. 3 
On the other hand, as mentioned in the previous section rapid deliquescence can lead to an increase 4 
in particle size that makes it more difficult for drugs to reach deep into the airways. Finding optimal 5 
values for both particle size and hygroscopicity is important for providing patients with the most 6 
efficiently delivered treatment with the least side effects, and is the primary motivation for this series 7 
of experiments. Additionally, a better understanding of the hygroscopic properties of drug molecules 8 
should inform which drugs are likely to be pre-wetted by the wicking effect of water uptake upon 9 
inhalation, thus kick starting the dissolution of drug particles upon impaction onto higher respiratory 10 
tract surfaces like the epithelium (Brain, et al., 2014). 11 
Investigations are ongoing into the hygroscopic behaviour of drug aerosols delivered by nebuliser e.g. 12 
(Haddrell, et al., 2014). However, the popularity of pMDI delivery for bronchodilation medication and 13 
the logistical difficulties involved in modelling the pharmacokinetic behaviour of medication inside the 14 
lung of a living creature mean that similar studies on pMDI-delivered drugs are justified. DPI 15 
formulations have been shown to be vulnerable to high humidity conditions (Janson, et al., 2016) and 16 
the lower particle velocity of DPI inhalations compared to pMDI (Ibrahim, et al., 2015) also implies 17 
that high humidity conditions are potentially of even great concern for DPI devices. However, the 18 
sudden change in humidity surrounding drug particles from both types of device upon inhalation mean 19 
that changes to particles from pMDIs also merit attention. 20 
It is worth noting that the lung deposition rate of pMDI-delivered material is normally less than 10% 21 
(Newman, et al., 1981) and with optimised inhalation technique and additional equipment such as 22 
spacers (Dolovich, et al., 1981) (Newman, 1996) maximum possible deposition appears to be around 23 
25% of the total inhaled dose. Since larger particles are more likely to impact or be excluded by the 24 
processes discussed above, concern over hygroscopic particle growth is justified. 25 
This series of experiments investigates the use of an optical trap to stably levitate drug aerosols 26 
released by popular pMDI devices and Raman spectroscopy to monitor signs of hygroscopic particle 27 
growth upon rapid increase in RH. The set up allows for the control of temperature and RH to more 28 
closely mimic the conditions inside the human lung than conventional cover slip analysis.  29 
 30 
2. Methods and Materials 31 
The combination of optical trap, Raman spectroscopy and model lung was first described in Tong et al 32 
2014 (Tong, et al., 2014).  The optical trap uses a counter propagating dual beam (CPDB) trap 33 
configuration first described by Rkiouak et al. (Rkiouak, et al., 2014) and deployed in several 34 
subsequent experiments (Tang, et al., 2014) (Jones, et al., 2015) (Hunt, et al., 2015). This trapping 35 
setup is remarkable because it is capable of stably trapping micron-sized solid particles of non-36 
spherical geometry for periods of time up to several hours. 37 
 38 
2.1 Counter propagating dual beam optical trap 39 
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The trapping beams were generated by a 1064 nm Nd:Yag laser (Ventus, Laser Quantum) passed 1 
through a beam splitter (Oz optics) and fibre-coupled into two single-mode fibres.  Each fibre output 2 
was delivered to beam expansion and collimation optics before entering the objective lenses. The 3 
laser power at output was 15 mW from the top objective lens and 10 mW through the bottom 4 
objective lens (figure 2). The asymmetry in power ensured that trapped particles were driven closer 5 
to the optical focus plane of the bottom objective through which the Raman laser is passed, ensuring 6 
better focus on the resulting images (Rkiouak, et al., 2014). The foci of the lasers were positioned ~10 7 
µm apart, which created a trapping volume large enough to stably hold 1-5µm particles for long 8 
periods. Once all useful observations had been collected from a trapped particle, the particle was 9 
allowed to fall under gravity to the cover slip by blocking the 1064 nm trapping beams. 10 
There are several reasons to prefer an optical trap to cover slip analysis. The most significant is that 11 
pharmaceutical aerosols are, until they reach the respiratory tract, suspended particles and attempts 12 
to recreate their conditions should be as close as possible. Interactions between collecting substrates 13 
and water can measurably alter the deliquescence point of hygroscopic particles (Eom, et al., 2014) 14 
with surfaces like glass reducing the deliquescence point of sodium chloride by 1.5% compared to a 15 
suspended particle.  Previous work in our group has also observed changes in particle efflorescence 16 
upon a cover slip compared to optical trap. Any particle landing on a cover slip will have part of its 17 
surface in contact with the cover slip rather than exposed to the surrounding air (see figure 1), so a 18 
hygroscopic particle will form a water layer beginning with a halo around the contact point with the 19 
cover slip rather than across the surface dictated by the particle’s geometry and density of hygroscopic 20 
sites. The shape of the resulting droplet and rate of adsorption will both be affected by the presence 21 
of a cover slip. 22 
 23 
Figure 1. An illustration of the influence of coverslips on the formation of water layers on 24 
hygroscopic particles. Optical trapping allows particles to remain suspended as they deliquesce in a manner 25 
more representative of particles in vivo. 26 
This is especially important in time-critical experiments such as those reported in this paper. Optical 27 
trapping represents the best current option for making detailed observations of physical and chemical 28 
changes on suspended particles in varying conditions, and yields better resolved Raman spectra than 29 
particles observed on a cover slip due to the removal of interfering spectral features associated with 30 
the composition of the cover slip.  Optical trapping is typically superior for single particle spectroscopy 31 
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when compared to other single particle levitation techniques, such as electrodynamic balances or 1 
acoustic trapping, because the optical setup ensures good alignment between the studied particle and 2 
spectroscopic probe (Hargreaves, et al., 2010). 3 
Optical trapping is easiest with spherical or spheroidal particles and droplets due to their symmetry 4 
(Ashkin, 1992). While the setup used in this work has demonstrated the capacity to trap non-spherical 5 
particles for periods of an hour or longer (Rkiouak, et al., 2014) (Tong, et al., 2014), particles that are 6 
closer to spheres are still easier to trap for the same reasons. 7 
2.2 Raman Spectroscopy 8 
Raman spectroscopy is a powerful technique for examining the functional groups and intermolecular 9 
interactions of substances, requiring very small sample masses and no sample preparation (Hirschfeld 10 
& Chase, 1986) (Vankeirsbilck, et al., 2002) and making it ideal for the analysis of micrometer-scale 11 
drug particles. Raman spectroscopy has much lower signal-to-noise ratio than competing infrared 12 
analysis techniques because of the visible range detection region, and because the scattering 13 
wavelengths are separate from those of the excitation laser, so the technique can be effective with 14 
very small samples whose absorption would be indistinguishable against a standard FT-IR beam 15 
(PerkinElmer Inc, 2008). These experiments use a Raman setup which collects back-scattered photons 16 
along the same path as the excitation laser, but filtering the excitation photons with a Razoredge 17 
dichroic mirror and longpass edge filter combination (SemRock). 18 
Raman scattering was generated using a 514.5nm Ar-ion laser (Innova 300C, Coherent), with a power 19 
of 4.3mW measured at the laser focus. Each Raman spectrum was generated by a 30 second exposure 20 
to the 514.5nm laser. This is longer than the residence time of particles in the respiratory system but 21 
is necessary to generate usable and reproducible spectra. These wavelength and power settings were 22 
selected based on previous experiments (Hunt, et al., 2013) as they were found to cause minimal 23 
heating of samples over long periods of exposure. Raman scattered light was collected in the region 24 
of 540-1830 cm-1. 25 
Wavelength calibration of the Raman spectrometer was carried out using a cover slip with raised sides 26 
containing pure liquid toluene. The spectrum is collected from a focal point within the bulk liquid, 27 
away from the surface of the cover slip to avoid interference. The position of spectral peaks for toluene 28 
is well characterized and these are used as a reference for wavelength calibration. 29 
2.3 Artificial Lung Chamber & Particle Imaging 30 
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 1 
Figure 2 Top-down (A) and side (B) views of the artificial lung chamber  2 
(High RH conditions here defined as >93% @ 20oC) 3 
The artificial lung (figure 2) was an aluminium chamber of internal dimensions approximately 10 x 2 x 4 
1cm, with borosilicate cover slip windows at the top and bottom to admit laser light and also at the 5 
sides to observe particles using a Mitutoyo M Plan Apo 20x objective lens connected to a CCD camera 6 
(Princeton Instruments, Spec10), opposite an LED source (Comar Optics). A monitor attached to the 7 
CCD camera allowed users to observe particles passing around, through and into the optical trap. 8 
RH and temperature were monitored using a Sensirion SHT-75 RH probe with a manufacturer-stated 9 
accuracy of ±1.8% RH and ±0.3oC. Raman spectra were collected within 3 minutes of reaching the 10 
desired RH. This is significantly longer than the 10 seconds recommended by the medical community 11 
for inhalation, holding an exhalation of a pMDI dose but is necessary for adjusting RH accurately and 12 
for developing clear and reproducible spectra. RH levels were altered using N2 gas sourced from boiled 13 
off liquid nitrogen, using a flow rate of ~200 cm3/min through a Bronkhorst MV-301 mass flow 14 
controller. A lower flow rate of 100 cm3/min was used for RH adjustment of the Salmeterol particles, 15 
since higher flow rates tended to dislodge the particles from the trap for reasons discussed in section 16 
3.3. The input and exhaust ports were located on the same face of the cell in order to generate slow 17 
flow conditions around trapped particles and thus minimise turbulence that might dislodge the 18 
particle. 19 
The gas was either run into the cell directly (low RH) or passed through a bubbler containing milli-Q 20 
grade deionized water before entering the cell (high RH). For very high RH conditions, a water reservoir 21 
was added inside the chamber. While the bubbler could provide RH up to ~90%, the reservoir could 22 
generate RH as high as 93% at 30oC and up to 98% at 20oC. 23 
Salmeterol xinafoate, fluticasone propionate and ciclesonide were analysed at ambient temperature 24 
at high and low RH. Salbutamol sulfate was analysed both at ambient temperature and at more 25 
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physiologically relevant temperatures by incubation of the microscope environment using Solent 1 
Scientific incubator components. 2 
2.4 pMDI injection 3 
To dispense the aerosolised drug into the artificial lung chamber, a simple connector was built for the 4 
pMDI outlet involving a flexible rubber cap with a rigid 6mm (internal diameter) PTFE tube protruding 5 
through it. The tube was connected to a similar tube on the side of the artificial lung by a short length 6 
of flexible silicone tubing. The chamber was washed sequentially in deionized water and methanol to 7 
minimise potential cross-contamination with other drugs. 8 
The propellant flow within the sample chamber carried material from each pMDI discharge into the 9 
path of the trapping beam. Drug particles passing across the side viewing window were illuminated by 10 
an LED and observed on a monitor. Scattering of the unfiltered trapping laser from a trapped particle 11 
was viewed on the same monitor to indicate the positional stability of the particle. 12 
Based on the stated mass per release of each drug, the density of the solid material (Zhejiang NetSun 13 
Co., Ltd., 2010), the assumption that an average particle is solid and has a volume of approximately 14 
10 µm3, a single release from each inhaler is estimated to deliver approximately 106 to 107 particles to 15 
the chamber.  However, many of these particles are lost by impaction onto the walls of the chamber. 16 
A single trapped particle, which is at least 2µm in diameter, has sufficient material to generate a 17 
Raman spectrum. 18 
2.5 SEM imaging 19 
Each drug was actuated onto a glass cover slip and coated with 10nm gold particles in a Polaron 20 
SC7640 sputter coater. The cover slips were attached to Agar Scientific 25mm double sided sticky 21 
carbon tabs prior to imaging on a Philips XL30 ESEM FEG. 22 
2.6 Chemical Structures of the asthma drugs investigated 23 
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 1 
Figure 3 Chemical structures of single molecules of salbutamol sulfate (a), salmeterol xinafoate (b), 2 
fluticasone propionate (c), and ciclesonide (d) 3 
Salbutamol sulfate particles were generated from a Salamol brand inhaler by Ivax Chemicals ltd. 4 
Salbutamol sulfate contains several polar groups and no long aliphatic chains, and its hygroscopic 5 
character has been documented (Tong, et al., 2014). Salmeterol xinafoate particles were produced 6 
from a “Serevent” brand inhaler produced by Cipla Ltd. Salmeterol also contains multiple polar groups 7 
but also a long aliphatic chain. Its hygroscopic properties are to be determined. 8 
 9 
Fluticasone propionate, generated from a “flixotide” brand inhaler, is manufactured by 10 
GlaxoSmithKline, and ciclesonide particles were generated by a “Ciclohale” brand inhaler also by Cipla 11 
Ltd. Ciclesonide is produced under license from Takeda UK Ltd. Fluticasone propionate and ciclesonide 12 
are both steroids and as such are relatively hydrophobic and are not expected to show hygroscopic 13 
properties. 14 
3. Results and Discussion 15 
3.1 Thermodynamic Calculations of Particle Hygroscopicity 16 
Thermodynamic calculations of aerosol particle hygroscopicity were carried out using the Extended 17 
Aerosol Inorganics Model (E-AIM) (Clegg, et al., 2001) (Engelhart, et al., 2011) (Ling & Chan, 2008).  E-18 
AIM is a thermodynamic model for predicting the water content of aerosol particles at different RHs.  19 
The model is appropriate for calculating the thermodynamic state of the drug aerosol for a given RH, 20 
however, the model does not take into account the time dependent kinetic limitations of water uptake 21 
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to the particle within the respiratory tract. Within E-AIM, model III is used and the UNIFAC model is 1 
chosen to calculate the water activities of the organic fraction of the investigated drugs within the 2 
particle at different RH.  The UNIFAC model parameterizes the molecular composition of the organic 3 
fractions of the investigated drug particle using a combination of structural and functional groups 4 
(Wittig, et al., 2003). The calculation of water activities of the sulfate group within salbutamol sulfate 5 
is also described by Clegg (Clegg & Brimblecombe, 1998). The type and quantity of UNIFAC parameters 6 
chosen to represent the four investigated drugs are provided in Table 1.  It is noted in some cases 7 
exact matches for molecular composition, using UNIFAC, of the investigated drugs are not possible 8 
and in such cases the closest match was used.  Standard dissociation constants for the carboxylic acid 9 
and amine functional groups were used.  The model assumes that both salbutamol sulfate and 10 
salmeterol xinafoate dissociate into their respective ions dependent upon their dissociation constants.  11 
The formation of solid salts (salbutamol sulfate and salmeterol xinafoate) is disallowed since the 12 
activity products of the salts are unknown.  Hence the modelled hygroscopicity provides an upper limit 13 
estimate.   14 
 15 
Table 1. UNIFAC parameters used for thermodynamic modelling of the four investigated drugs. Note 16 
that the salmeterol xinafoate is modelled as two separate molecules: salmeterol and xinafoate.  Also 17 
note that the sulphate in salbutamol sulphate is not modelled using UNIFAC hence its omission from 18 
the table. 19 
UNIFAC Group Salmeterol Xinafoate Salbutamol Fluticasone 
propionate 
Ciclesonide 
Alkane (CH3) - - 3 4 3 
Alkane (CH2) 10 - 1 1 9 
Alkane (CH) 1 - 1 4 6 
Alkene 
(CH=CH) 
- - - 1 1 
Alkene (CH=C) - - - 1 1 
Aromatic 
carbon (ACH) 
8 6 3 - - 
Aromatic 
carbon (AC) 
4 4 3 - - 
Alcohol (OH) 3 1 3 1 1 
Carboxylic 
acid (COOH) 
- 1 - - - 
Carbonyl 
(CH2CO) 
- - - 2 2 
Ether (CH2O) 1 - - - - 
Ether (CHO) - - - - 2 
Secondary 
amine 
(CH2NH) 
1 - 1 - - 
12 
 
Acetate 
(CH2COO) 
- - - 1 1 
Fluoroalkane 
(CF) 
- - - 3 - 
  1 
 2 
The output from E-AIM allows for the prediction of the drug molecule hygroscopicity (Clegg, et al., 3 
2001) (Engelhart, et al., 2011) (Ling & Chan, 2008). Figure 4 shows the mass growth factors for the 4 
four investigated drugs. Mass growth factor is defined as the mass increase, for a given RH, normalized 5 
to the dry mass. It can be seen that Figure 4 predicts two distinct types of interaction. The beta-2 6 
agonists (salbutamol sulfate and salmeterol xinafoate) contain a higher proportion of hydrophilic 7 
groups and are thus predicted to be strongly hygroscopic, while the more lipophilic steroids 8 
(ciclesonide and fluticasone propionate) are expected to collect little water from the air even under 9 
near water saturated conditions. It is noted, that the bulk thermodynamic calculations in E-AIM do 10 
not take into account the crystal structure of solid particles which may block access to hydrophilic sites 11 
and prevent otherwise hydrophilic molecules from interacting with water in the air.  Furthermore, the 12 
model runs do not take into account possible deliquescent barriers to water uptake due to the lack of 13 
product activity data. 14 
Ferron’s kinetic model (Ferron, 1977), as used in the International Commission on Radiological 15 
Protection (ICRP, 1994) provides a parameterization with which to estimate of the time dependent 16 
growth of hygroscopic particles.  pMDI particles are typically generated in the size range 2 – 5 m to 17 
optimally deliver drugs to the central regions of the lung. The Ferron model suggests that a 18 
hygroscopic particle of initial size of 2–5 m diameter will reach approximately 80–50% of its 19 
equilibrium size, respectively, within a typical 2–3 s long inhalation. 20 
 21 
 Figure 4 Influence of relative humidity on particle diameter predicted from chemical bonding  22 
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3.2 Drug Particle Crystallography 1 
The Mercury 3.6 program (Macrae, et al., 2006) was used to simulate the crystal structure of all drugs 2 
whose structures had been added to the Cambridge Structural Database run by the Cambridge 3 
Crystallographic Data Centre (CCDC, 2015). 4 
 5 
Figure 5 Model unit cells of salbutamol sulfate (a), fluticasone propionate (b), and ciclesonide (c). Salmeterol xinafoate's 6 
unit cell was not available at time of writing. Hydrogen bonding within the unit cell is illustrated with a cyan line, while 7 
hydrogen bonding external to the unit cell (thus contributing to hygroscopic behaviour) are illustrated with red dotted 8 
lines. 9 
The chemical structure of salbutamol sulfate (figure 5a) shows hydrophilic sites across the molecule. 10 
The most likely crystal form generated by rapid solvent evaporation in air was first described in 1978 11 
(Leger, et al., 1978), with an 8 molecule unit cell (figure 5a) that shows hydrogen bonding sites on 12 
every face. Hygroscopic behaviour is inferred from this structure and has been demonstrated in 13 
previous experiments at room temperature (Tong, et al., 2014). 14 
Salmeterol is not found in the Cambridge Structural Database. Solid structures are variously described 15 
as either amorphous, or needle-like or plate-like crystals depending on the exact conditions of 16 
manufacture (York & Hanna, 1994) (Barjoan & Clotet, 2009). Salmeterol xinafoate is bound together 17 
by hydrogen bonding of the δ-positive amine group on salmeterol to the δ-negative carboxylic acid 18 
group on the xinafoic acid. The two groups are expected to cancel their respective charges, leaving 19 
few hydrophilic sites open to interaction with water while the particle is in a solid state. 20 
14 
 
As a steroid, fluticasone is expected to be lipophilic (Lipworth & Jackson, 2000). The structure of 1 
fluticasone (figure 5b) does have a number of polar groups. However, the documented crystal 2 
structure (Cejka, et al., 2005) describes a plate-like structure with any hydrogen bonding occurring 3 
along the plane of growth (figure 5b) resulting in water interaction only along edges, and likely to 4 
result in little or no hygroscopic behaviour. 5 
Ciclesonide (figure 5c) is found as either needle-like (Phull, et al., 2012) or needle-like and spherulitic 6 
crystals as well as amorphous solids (Feth, et al., 2007) depending on solvent type and evaporation 7 
time. Ciclesonide has multiple polar groups but the model unit cell described by Feth et al describes 8 
most of the oxygens arranged inside the crystal with the hydrophobic sites facing outward. Limited 9 
hydrogen bonding due to the hydroxyl and ketone groups on adjacent molecules have the potential 10 
to attract water molecules to crystal faces, but the hydrophobic nature of the rest of the exposed 11 
molecule implies that hygroscopic behaviour is unlikely. 12 
3.3 SEM imaging and Trapping Logistics 13 
 14 
Figure 6 SEM images of: (a) salbutamol sulphate, (b) salmeterol xinafoate, (c) fluticasone propionate & (d) ciclesonide 15 
SEM images of the drug particles were collected under dry conditions in order to determine shape and 16 
ease of capture. The likelihood of a particle being successfully caught in the optical trap is dictated by 17 
both particle shape and the number of particles generated per release. Salbutamol sulfate had been 18 
optically trapped previously on the same apparatus (Tong, et al., 2014). The thick, needle like shape 19 
of salbutamol sulfate particles (figure 6a) is well suited to entrapment for reasons detailed in section 20 
2.4, and the 100 µg per release dose of the available inhalers resulted in a successfully suspended 21 
particle roughly once for every two releases. Salmeterol xinafoate was significantly harder to trap and 22 
retain than the others due to a combination of its low dose (20 µg per release) and flat, platelike 23 
aggregate structure (figure 6b). Fluticasone has a similar crystal structure to salmeterol but a much 24 
higher dose (250 µg per release) and was more reliably trapped than salbutamol sulfate. Ciclesonide 25 
15 
 
was similar in trapping frequency to fluticasone since its lower dose (160 µg per release) was balanced 1 
by a more spherical particle shape (figure 6d). 2 
3.4 Raman spectrum changes from hygroscopic properties and additional compounds 3 
Hydrogen bonding with water molecules adjacent to the polar groups of organic molecules expands 4 
the range of vibrational energy states that can generate Raman scattering photons. This effect allows 5 
water uptake by hygroscopic particles to be monitored by Raman spectroscopy. 6 
All four drugs use hydrofluoroalkane HFA 134a/Norflurane as a propellant. The salbutamol and 7 
ciclesonide inhalers also report anhydrous ethanol among their ingredients. Norflurane contains four 8 
C-F bonds, each of which generate a distinctive Raman scattering peak at 1234 cm-1. This peak is not 9 
expected to be visible in the Raman spectra of the drug molecules, apart from Fluticasone which has 10 
3 C-F bonds of its own, due to Norflurane’s low boiling point (-26.5oC, (Lide, 1991)) at atmospheric 11 
pressure causing all of the propellant to boil off before readings can be collected. The spectra collected 12 
from particles other than fluticasone do not show peaks in the C-F stretching region, which implies 13 
that all propellant boils off before the particles are scanned. 14 
3.5 Salbutamol sulfate / Salamol™ 15 
3.5a Raman spectra and structural information 16 
Each salbutamol molecule contains a single phenol group, two aliphatic hydroxyls and a secondary 17 
amine. One molecule of salbutamol contains two ionised salbutamol molecules bound to a single 18 
sulfate group. The S=O symmetric stretches on the sulfate show a small but distinctive peak at 1154 19 
cm-1. The largest peaks in the salbutamol spectrum correspond to –CH wagging at 656 cm-1, aromatic 20 
ring vibration at 752 cm-1, C-C-O stretches in relation to the aliphatic hydroxyls at 784 cm-1, asymmetric 21 
hydroxyl stretches at 969, 977 and 1008 cm-1, phenyl ring vibrations at 1059 and 1074cm-1, a 22 
prominent CH stretch at 1257cm-1 (this bond can be found in figure 3 just above the ring) CH2 and 23 
CHOH vibrations again from the aliphatic hydroxyls at 1360 cm-1, a broad ring stretching peak around 24 
1450cm-1 followed by a CH2-N amine peak at 1463cm-1, and finally a strong peak at 1615cm-1 25 
corresponding to the phenolic C-OH stretch. All of these peaks (figure 7) correspond well with those 26 
found in the literature (Ali, et al., 2009). 27 
3.5b Impact of RH and Temperature on salbutamol spectra 28 
16 
 
 1 
Figure 7 Raman spectra of optically trapped salbutamol sulfate particles at a range of RH and temperatures. 2 
Above salbutamol’s deliquescence point of 92% RH, peak broadening is visible at the C–OH peak at 1008cm-1 3 
and at the C–NH peak at 1463cm-1, signifying water interaction with the bonds. 4 
RH above 92%, the deliquescence point identified by Tong et al (Tong, et al., 2014), could not be 5 
maintained at physiological temperature (37oC) with the available equipment, so measurements were 6 
taken at 30oC- the highest temperature at which >92% RH could be maintained. The particle trapped 7 
at 98% RH and 30oC was small, hence the poorer signal/noise ratio. The contrast between the 8 
relatively dry and relatively wet particles is clear to see as the peaks corresponding to hydrophilic 9 
bonds in the wet particles are broader, and some peaks such as the hydroxyl peak at 1008cm-1 and 10 
the amine peak at 1463cm-1 are more pronounced. 11 
The spectral traces, recorded at similar RH but under contrasting temperatures, are very similar. 12 
Within the temperature range investigated (20-38oC), there are no observable temperature effects 13 
upon particle deliquescence.  The deliquescence RH is measured to be ca. 92% RH in agreement with 14 
the measurement of Tong et al (Tong, et al., 2014).  This implies that the temperature gradient 15 
experienced in the trajectory from pMDI to lung is likely to be unimportant in determining particle 16 
hygroscopicity; RH is the dominant determinant of particle hygroscopicity. 17 
The modelling results from E-AIM suggested that salbutamol sulfate would show significant 18 
hygroscopicity if a deliquescence phase transition occurred.  The experimental results confirm this 19 
model prediction.  The presence of a phase transition and significant water uptake is in line with the 20 
high reported solubility of salbutamol sulfate (14.1g/L, (Walkowsky & He, 2003). 21 
3.6 Salmeterol xinafoate / Serevent™ 22 
3.6a Raman spectra and structural information 23 
Salmeterol xinafoate contains several aromatic rings, an ether group, a benzoic acid and a secondary 24 
amine. Benzoic acid is distinct from both aromatic rings and carboxylic acids due to the increased 25 
C-OH C-NH 
17 
 
conjugation (Kwon, et al., 1994) and shows distinctive peaks in the solid state at 1627 cm-1, 994 cm-1 1 
and 788 cm-1. These peaks are all present in our spectra (figure 8). Ring stretches are clearly visible at 2 
1580-1616 cm-1, 1400-1420 cm-1 (the multiple strong peaks denoting ring stretches shifted by the 3 
various adjacent functional groups) and symmetric ring stretches are visible at 1000-1028 cm-1, 1215 4 
and 1257 cm-1. A strong amine vibration peak is visible at 1204 cm-1. A sharp peak at 730 cm-1 5 
corresponds to rotational peaks from CH2 groups, as would be expected by a molecule with a long 6 
aliphatic chain like salmeterol. The ether group can be identified by small peaks at 554 and 1145 cm-7 
1. These spectra correspond well with previously published, well-defined Raman spectra (Ali, et al., 8 
2008a). 9 
Repeated exposure to the Raman laser caused some fluorescence effects in salmeterol xinafoate 10 
particles, so each spectrum had to be recorded on a freshly captured particle. The Raman laser was 11 
blocked except during the collection of spectra in order to minimise the effect.  The fluorescence 12 
activity that occurs in salmeterol xinafoate after prolonged exposure to the Raman laser may possibly 13 
be avoided in future experiments by using a longer excitation wavelength. 14 
 15 
3.5b Impact of RH on salmeterol spectra 16 
 17 
Figure 8 Raman spectra of salmeterol xinafoate at a range of RH values. Even at 95% RH, the amine vibrational 18 
peak at 1204cm-1 and carboxylic acid stretching peak at 1420cm-1 do not show signs of broadening, contrary to 19 
the predicted behaviour modelled by E-AIM. Intensity changes on the aromatic ring stretches at different RH are 20 
highlighted in red. 21 
According to the Raman spectra collected in figure 8, salmeterol xinafoate does not demonstrate any 22 
visible broadening around peaks corresponding to either salmeterol’s amine group or the carboxylic 23 
acid group on its xinafoic acid partner upon RH enhancement.  This suggests that the salt does not 24 
undergo a deliquescent phase transition.  The modelling results from E-AIM suggested that salmeterol 25 
C-NH O=C-O 
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xinafoate would show significant hygroscopicity if a deliquescence phase transition occurred.  The 1 
observed lack of deliquescence is in line with the low predicted solubility of salmeterol xinafoate (22.6 2 
mg/L according to ALOGPS (Tetko, 2001)). 3 
The hygroscopic behaviour of salmeterol xinafoate, as predicted by E-AIM, may be limited by the steric 4 
hindrance of the hydrophilic sites by hydrophobic structures arranged around them in solid crystals. 5 
The relative enhancement of peaks corresponding to aromatic ring stretches at 650, 1000 and 1580 6 
cm-1 imply some interaction with water around some or all of the aromatic rings in salmeterol 7 
xinafoate at >88% RH. Most likely, the presence of the hydroxyl and carboxylate groups on the 8 
aromatic xinafoate section of the drug enhances water interaction. 9 
3.4 Fluticasone propionate / Flixotide 10 
3.4a Raman spectra and structural information 11 
Fluticasone contains several distinctive bonding types that would be expected to yield distinctive 12 
peaks in any resulting Raman spectra: a phenone, an ester, a thioether and three C-F bonds across the 13 
molecule. Fluticasone has been imaged by Raman spectroscopy previously and its spectra interpreted 14 
in depth (Ali, et al., 2008b) (Rogueda, et al., 2011) (Theophilus, et al., 2006) (Wang, et al., 2014), which 15 
provides useful references for the spectra generated here. 16 
The raw fluticasone propionate spectra contained a very sharp and strong peak at 640 - 650 cm-1. This 17 
peak was not observed in other spectra in the literature.  We believe this peak to be an artefact caused 18 
by second harmonic resonance effect from the 1064 nm trapping laser.  Confirmation of the spectral 19 
artefact was achieved by measuring spectra of fluticasone propionate recorded on the cover slip 20 
without the trapping laser present.  These spectra did not contain the peak.  We have removed this 21 
artificial peak from the spectra shown in Figure 9.  22 
The strongest peak in the spectrum of fluticasone is the C=O vibration at 1659cm-1, followed by the –23 
CH3 symmetric stretch (there are 4 –CH3 groups in Fluticasone) at 1606cm-1. –CH2 and –CH stretches 24 
occur at around 1380 and 1330 cm-1 respectively and highly distinctive C-F and S-C-F bands occur at 25 
1234cm-1 and 1022cm-1. Fluticasone is the only compound among the samples that contains a C-F 26 
bond, and generated the only spectra showing C-F stretching peaks. This implies that that in all 27 
samples the Norflurane propellant had fully evaporated prior to analysis. The phenone group registers 28 
as an OOH/CCH aromatic deformation peak at 888cm-1. A small C-H wagging peak can be seen at 29 
around 700cm-1. 30 
3.4b Impact of RH on fluticasone spectra 31 
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 1 
Figure 9 Raman spectra of fluticasone propionate at a range of RH values. The C-F stretching peak at 888 cm-1 2 
is present in this spectrum but not the others, confirming that the Norflurane propellant discussed in section 3.4 3 
has boiled off 4 
The spectrum collected at 80% RH was from a small particle- around 1µm in diameter. This accounts 5 
for the greater noise in the signals. Otherwise, no peaks are displaced or strongly deformed by the rise 6 
in relative humidity. Fluticasone shows no signs of hygroscopic behaviour, in agreement with the 7 
results from E-AIM. Water solubility is low (11.4 mg/L) as predicted by ALOGPS (Tetko, 2001). 8 
3.5 Ciclesonide / Alvesco™ 9 
3.5a Raman spectra and structural information 10 
Ciclesonide (Feth, et al., 2008) has a diverse selection of functional groups, which generates a 11 
complicated Raman spectrum. The largest peak at 1654cm-1 (figure 10) represents the stretching 12 
vibration of an α, β-unsaturated carbonyl, while the adjacent peak at 1601cm-1 shows the 13 
neighbouring C=C bond. Ciclesonide contains four -CH3 groups and this corresponds to another large, 14 
broad peak at 1443cm-1. The three ether bonds generate another large peak at 1112cm-1, and the 15 
single ester linkage appears at 1242cm-1. Ciclesonide has a single hydroxyl group attached to a six-16 
membered saturated ring, and a matching “cyclic alcohol” stretch appears at 1029cm-1. The C-C 17 
stretches of the two saturated six-membered rings are found at 963cm-1. Multiple small peaks around 18 
800-900cm-1 represent ring deformation in the phenol group adjacent to the saturated rings. Another 19 
region of small peaks around 1330cm-1 corresponds to the various symmetric and antisymmetric 20 
stretches of the isopropyl group. 21 
3.5b Impact of RH and Temperature on Ciclesonide Spectra 22 
C-F 
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 1 
Figure 10 Raman spectra of ciclesonide at a range of RH values. The spectra show no signs of hygroscopic 2 
behaviour at up to 98% RH. 3 
As a steroid, ciclesonide is not very hydrophilic and does not contain many polar groups. The crystal 4 
structure shows very little opportunity for water uptake on surfaces, and E-AIM predicts that 5 
ciclesonide has the lowest hygroscopic potential of any of the drugs analysed. Calculated water 6 
solubility is also the lowest of all the drugs (1.57mg/L, (Tetko, 2001)). It would not be expected to show 7 
hygroscopic behaviour, and no such behaviour was observed in the Raman spectra compiled in figure 8 
10. 9 
 10 
3.6 Specific advantages and limitations of procedure to drug delivery 11 
The advantages of this setup and analytical technique to the examination of inhalable drugs do merit 12 
some discussion in addition to the general benefits of optical trapping over cover slip analysis 13 
documented in section 2.1. The current setup can monitor particle size with an external camera as 14 
well as directly monitoring water interactions with hydrophilic functional groups on particles by 15 
examining the Raman spectrum. On-board RH monitoring can determine deliquescence points for new 16 
drugs, or verify those of existing drugs, to a high degree of accuracy, factoring in the crystal structures 17 
of particles as well as their chemical structure in a manner that is difficult to reproduce with software 18 
modelling alone.  At present, the main limitation of the technique is the length of time required to 19 
collect each Raman spectrum which is longer than the pMDI inhalation cycle.  20 
 21 
4. Conclusions 22 
=C=O 
21 
 
This series of experiments has demonstrated a viable technique for examining individual particles of 1 
inhalable drugs supplied by pMDIs. With little modification, such as by attaching a vacuum pump to 2 
the outlet port of the sample chamber, this experimental setup may also be used to examine single 3 
particles from DPI devices. 4 
The Raman spectra of four optically trapped drug particles (salbutamol sulfate, salmeterol xinafoate, 5 
fluticasone propionate and ciclesonide) were measured within a model lung. The model lung allowed 6 
for modification of local RH to test the drugs for hygroscopic behaviour, while the optical trap 7 
eliminated any surface effects from water droplets forming around a solid particle on a cover slip. 8 
Raman spectroscopy allowed for the direct observation of the hydrogen bonding with water in 9 
hydrophilic groups, where the broadening of peaks indicates hygroscopicity. 10 
Spectral peak broadening was observed in salbutamol sulfate particles above their deliquescence 11 
point at 92% RH, at room temperature and more physiologically relevant temperatures, while spectra 12 
remained similar to dry particles at lower RH regardless of temperature within the observed range. 13 
Salmeterol xinafoate shows some spectral changes to the intensities of the peaks corresponding to its 14 
aromatic rings, but does not show any changes to the more hydrophilic functional groups which is 15 
interpreted as no deliquescence at RH up to 95%. Fluticasone propionate and ciclesonide show no 16 
hygroscopic properties at all, as would be expected with their lipophilic composition, low water 17 
solubility and the modelled particle growth factors generated using the E-AIM model. 18 
 19 
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